All In MedTech

Device Trial Radar · NCT07943663

Development of a Virtual Health Care Platform in Heart Failure Patients Transitioning From Hospital to Home

Feasibility and Performance Evaluation of nucleusRx Virtual Care Platform for Care Management of At-home Heart Failure Patients

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitation

Status

Enrolling by invitation

Enrollment

15

Planned (sponsor's estimate)

Start

Nov 26, 2025

Primary completion

Dec 10, 2026

Study completion Jan 15, 2027

Sponsor

Lead sponsor
nucleusRx IncNot on our public-company list
Sponsor type
Industry
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
First posted
Nov 17, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Device feasibility
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 89 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Study will be performed with fifteen (15) Heart Failure (HF) patients for remote monitoring of health and medication adherence following hospital discharges. Participants will be enrolled into two groups: Group 1 (chronic) will be enrolled on Day 30 to 180 post hospital discharge and monitored for 30 days; Group 2 (Acute) will be enrolled on Day 1-3 of hospital discharge after recent HF episodes and monitored for 30 days. Each participant will receive a Pill Dispenser being developed by the study sponsor, a BP machine, a weighing scale and a smartphone loaded with the software developed by the study sponsor that can collect and summarize participant's health data for study physician's/nurse's evaluation. Both BP machine and weighing scale record participant's data automatically to send to the study team physician/nurse for evaluation of his/her health. Outpatient pharmacy will deliver 30 days (+7) of medications as prescribed by the patient's physician in the standard pharmacy vials, and the patients will procure them from their chosen pharmacy outlet. Prescription details for medications will also be sent to the participant's mobile phone. Medications will be uploaded in the dispenser on Day 1 by the patient in presence of a visiting nurse (a member of the study team) who will review and explain medication records with the patient. Nurse will also review and set up the machine as necessary for the daily wellness parameters to be measured and entered by the patient. Data will be collected automatically for the length of the study (30 days). A 24-hr telephone number will be available to each patient to contact study nurse for any issues related to medication dispensing and/or health. Devices will be returned to the study investigator on Day 30 and the remaining pills in the pill dispenser will be manually counted by the study nurse in both groups for comparing against the automatically collected data.

Conditions

  • Heart Failure - NYHA II - IV

Interventions

  • There is no other intervention, only dose changes using the device if clinically needed to treat the disease during the studyDevice

    The embedded software of the device connects with the patient's electronic health record (EHR) and provider's dashboard system to collect prescription information and control the dispenser through an interactive Q\&A with patient's mobile phone. Patient/caregiver is trained to be reminded of the programmed medication or dose changes through the device voice prompt and/or notifications on the NRX mobile phone app. The changed medication or its dose as requested by the investigator will be dispensed from the NRX dispenser following an authentication by the patient.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Medication Compliance: If device can dispense each specific medication following the directions as prescribed by the doctor through the EHRTime frame: 30 days
  2. Physiological measures of Blood Pressure (systolic and diastolic): If blood pressure is measured daily as directed by the treating physician during the studyTime frame: 30 days
  3. Monitoring the changes in body weight in pounds (Lb) between days or within a weekTime frame: over 30 says of the study

1 more outcomes with a free account

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • UH Portage Medical Center

    Ravenna, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.